AstraZeneca’s shares have risen 18.4% year to date compared with the industry’s 23.2% growth. Image Source: Zacks Investment Research If approved, this will be the first approval for Imfinzi ...

WILMINGTON, DE — AstraZeneca has announced positive high-level results from its Phase III POTOMAC trial assessing the efficacy of IMFINZI® (durvalumab) combined with standard-of-care Bacillus ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...

BARCELONA, Spain — An AstraZeneca immunotherapy ... The regimen using Imfinzi, the company’s anti-PD-L1 checkpoint inhibitor, cut the risk of death by 25% compared to treating patients ...

AstraZeneca also shared high-level results from the NIAGARA Phase 3 trial showing Imfinzi in combination with chemotherapy in bladder cancer Addition of Imfinzi did not increase discontinuation ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive bladder cancer (MIBC). Now, detailed data show exactly how Imfinzi ...

Imfinzi plus chemotherapy followed by Imfinzi ... and time to second subsequent therapy. Concurrently, AstraZeneca announced that starting June 1, 2024, eligible patients will pay no more ...

April 5 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Friday its blockbuster cancer drug Imfinzi helped improve survival in patients in the early stages of an aggressive type of lung ...

Nov 14 (Reuters) - Drugmaker AstraZeneca (AZN.L), opens new tab said on Tuesday its cancer drug Imfinzi given along with chemoradiotherapy (CRT) failed to meet its main goal in a late-stage trial ...

AstraZeneca AZN announced positive results from the ongoing phase III EMERALD-I study, which is evaluating Imfinzi (durvalumab) as a combination therapy in hepatocellular carcinoma (HCC), the most ...